Skip to main content
UniHealth

Doctor search

George Willard Sledge, MD

Medical Oncology · Stanford

NPI 1780640318

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1
Since medical school
43 years
Tulane University School of Medicine, 1983

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sledge’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence C55993 · Current

Licensed to practise in California · since 2013 · expires 2026-11-30 · Tulane University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Internal Medicine
  • American Board of Internal Medicine - Medical Oncology

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$5,365

Medicare paid this office $5,365 for 32 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Short return visit (20+ min)16$1,010$56

Who their Medicare patients are

32 Original Medicare patients in 2024. Average age 74 · Health risk score 1.77. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: Cancer 75% · High blood pressure 56%.

The office billed $18,989, Medicare allowed $7,074 and paid $5,365; for 61 services of 5 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20243261741.77$18,989$5,365
20234588731.82$24,885$7,863
202285180741.70$68,273$15,044
2021113226731.41$82,971$20,099
202097208731.43$60,824$13,152
201986164731.50$16,460$10,855
201892186721.37$19,876$13,947
201785167721.49$25,721$11,013
201686198731.43$35,631$12,986
201590187721.40$33,177$11,456
201481175701.10$31,860$10,769
20133749721.29$9,863$3,367

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Original Medicare services billed in 2023
Return visit (30+ min)20$2,952$89
Long return visit (40+ min)13$2,793$133
Short return visit (20+ min)26$1,993$60

2022: 3 services

Original Medicare services billed in 2022
Return visit (30+ min)38$6,146$87
Long return visit (40+ min)20$4,299$123
Short return visit (20+ min)48$3,327$54

2021: 4 services

Original Medicare services billed in 2021
Return visit (30+ min)48$7,465$87
Long return visit (40+ min)23$4,791$123
Short return visit (20+ min)52$3,618$52
New patient visit (60+ min)19$3,102$163

2020: 3 services

Original Medicare services billed in 2020
Return visit (30+ min)39$5,733$68
Short return visit (20+ min)58$2,751$39
Long return visit (40+ min)11$1,572$92

2019: 3 services

Original Medicare services billed in 2019
Return visit (30+ min)29$3,397$65
Short return visit (20+ min)53$2,922$42
Long return visit (40+ min)17$2,625$94

2018: 4 services

Original Medicare services billed in 2018
Long return visit (40+ min)19$4,293$95
Return visit (30+ min)33$3,912$66
New patient visit (60+ min)22$3,024$137
Short return visit (20+ min)44$2,326$42

2017: 3 services

Original Medicare services billed in 2017
Return visit (30+ min)31$4,585$67
Short return visit (20+ min)49$2,347$39
Long return visit (40+ min)16$2,192$100

2016: 3 services

Original Medicare services billed in 2016
Return visit (30+ min)35$5,463$67
Long return visit (40+ min)17$3,171$99
Short return visit (20+ min)52$2,795$41

2015: 3 services

Original Medicare services billed in 2015
Return visit (30+ min)39$4,438$64
Short return visit (20+ min)59$3,350$41
Long return visit (40+ min)13$1,878$99

2014: 3 services

Original Medicare services billed in 2014
Return visit (30+ min)33$4,195$65
Short return visit (20+ min)56$3,412$40
New patient visit (60+ min)13$1,944$150

2013: 2 services

Original Medicare services billed in 2013
Return visit (30+ min)14$1,285$68
Short return visit (20+ min)19$832$44

Drugs they prescribed that Part D paid

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their 37 Part D prescriptions in 2021. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

Year by year

Part D prescribing by year
202220NoneNoneNone$2,240
202137140% (0)None$10,068
20206418None25%$79,186
201996300% (0)17%$172,788
2018116350% (0)23%$237,739
20178029NoneNone$31,651
201684310% (0)None$79,006
2015121350% (0)10%$42,748
2014126310% (0)21%$112,561
201316353None16%$92,687

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2021: 1 drug

Part D drugs prescribed in 2021
Anastrozole22$525$24

2020: 2 drugs

Part D drugs prescribed in 2020
Exemestane12$5,249$437
Anastrozole30$314$10

2019: 2 drugs

Part D drugs prescribed in 2019
Tamoxifen Citrate16$1,118$70
Anastrozole44$746$17

2018: 3 drugs

Part D drugs prescribed in 2018
Ibrance13$155,270$11,944
Exemestane15$9,998$667
Anastrozole54$1,153$21

2017: 1 drug

Part D drugs prescribed in 2017
Anastrozole37$794$21

2016: 3 drugs

Part D drugs prescribed in 2016
Anastrozole33$927$28
Letrozole18$634$35
Tamoxifen Citrate17$479$28

2015: 4 drugs

Part D drugs prescribed in 2015
Exemestane17$6,893$405
Letrozole25$1,012$40
Anastrozole44$921$21
Tamoxifen Citrate12$378$32

2014: 3 drugs

Part D drugs prescribed in 2014
Exemestane14$4,622$330
Anastrozole53$1,173$22
Letrozole15$420$28

2013: 4 drugs

Part D drugs prescribed in 2013
Exemestane33$16,061$487
Anastrozole51$2,014$39
Venlafaxine Hcl Er14$519$37
Alendronate12$95$8

Money from drug and device companies

$6,800 in 2022

Industry payments by year
202222$6,800$6,800
202133$4,400$4,412
202022$3,050$3,050
2019522$25,000$35,730

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Novartis PharmaceuticalsKisqali$3,600
1 payment
  • Consulting for Kisqali · 2022-05-23 · $3,600
Lilly USAVerzenio$3,200
1 payment
  • Paid to speak or teach for Verzenio · 2022-02-25 · $3,200
See all 2 published payments
Every published payment
Novartis PharmaceuticalsConsulting · 2022-05-23Kisqali$3,600
Lilly USAPaid to speak or teach · 2022-02-25Verzenio$3,200
See earlier years (2021, 2020, 2019)

2021: $4,412

Payments by company in 2021
Novartis PharmaceuticalsKisqali$3,000
1 payment
  • Consulting for Kisqali · 2021-06-21 · $3,000
Eli Lilly andNone$1,400
1 payment
  • Consulting · 2021-08-05 · $1,400
Gilead SciencesNone$12
1 payment
  • Education · 2021-06-01 · $12

2020: $3,050

Payments by company in 2020
Varian Medical SystemsRadiation Oncology$2,000
1 payment
  • Paid to speak or teach for Radiation Oncology · 2020-10-29 · $2,000
Eli Lilly andNone$1,050
1 payment
  • Consulting · 2020-08-12 · $1,050

2019: $35,730

Payments by company in 2019
Radius HealthNone$25,000
4 payments
  • Consulting · 2019-10-17 · $2,500
  • Consulting · 2019-06-20 · $7,500
  • Consulting · 2019-03-14 · $7,500
  • Consulting · 2019-01-10 · $7,500
Eli Lilly andVerzenio$10,438
15 payments
  • Meals · 2019-12-24 · $5
  • Travel · 2019-12-24 · $629
  • Meals · 2019-12-24 · $24
  • Meals · 2019-12-24 · $39
  • Travel · 2019-09-26 · $9,368
  • Travel for Verzenio · 2019-09-06 · $14
  • Travel for Verzenio · 2019-09-06 · $17
  • Meals for Verzenio · 2019-09-06 · $15
  • Travel for Verzenio · 2019-09-06 · $85
  • Travel for Verzenio · 2019-09-06 · $85
  • Travel for Verzenio · 2019-09-06 · $17
  • Travel for Verzenio · 2019-09-06 · $14
  • Meals for Verzenio · 2019-09-06 · $99
  • Meals for Verzenio · 2019-09-06 · $14
  • Meals for Verzenio · 2019-07-31 · $15
Seattle GeneticsNone$109
1 payment
  • Meals · 2019-10-21 · $109
Varian Medical SystemsNone$97
1 payment
  • Meals · 2019-10-15 · $97
Genentech USAAvastin$85
1 payment
  • Meals for Avastin · 2019-09-28 · $85

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Novartis Pharmaceuticals Corporation · Ribociclib Standard Endocrine Therapy in Patients With Hr Her2 Early Bc at High Amp Intermediate Risk for Recurrence · 2020Their institution$607,436
Novartis Pharmaceuticals Corporation · Ribociclib Standard Endocrine Therapy in Patients With Hr Her2 Early Bc at High Amp Intermediate Risk for Recurrence · 2021Their institution$370,384
Novartis Pharmaceuticals Corporation · Ribociclib Standard Endocrine Therapy in Patients With Hr Her2 Early Bc at High Amp Intermediate Risk for Recurrence · 2022Their institution$302,613
Novartis Pharmaceuticals Corporation · An Umbrella, Randomized, Controlled, Pre-Operative Trial Testing Integrative Subtype-Targeted Therapeutics in Estrogen Receptor-Positive, Her2-Negative Breast Cancer · 2023Their institution$210,622
PFIZER INC. · A Phase 1b Dose Escalation Trial of Human Anti41bb Agonistic Antibody Pf05082566 in Combination With Adotrastuzumab Emtansine Or Trastuzumab in Patients With Her2positive Advanced Breast Cancer · 2022Their institution$164,576
PFIZER INC. · A Phase 1b Dose Escalation Trial of Human Anti41bb Agonistic Antibody Pf05082566 in Combination With Adotrastuzumab Emtansine Or Trastuzumab in Patients With Her2positive Advanced Breast Cancer · 2020Their institution$102,612
Genentech, Inc. · Patricia · 2020Their institution$44,069
PFIZER INC. · A Phase 1b Dose Escalation Trial of Human Anti41bb Agonistic Antibody Pf05082566 in Combination With Adotrastuzumab Emtansine Or Trastuzumab in Patients With Her2positive Advanced Breast Cancer · 2021Their institution$39,466
Eli Lilly and Company · Monarch 2- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With Or Without Abemaciclib, A Cdk4 6 Inhibitor, for Women With Hormone Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer · 2022Their institution$36,995
Eli Lilly and Company · Monarch 2- A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Fulvestrant With Or Without Abemaciclib A Cdk4 6 Inhibitor for Women With Hormone Receptor Positive Her2 Negative Locally Advanced Or Metastatic Breast Cancer · 2023Their institution$36,669
Genentech, Inc. · A Phase III Trial in Adjuvant Her2 Bc Pts · 2020Their institution$26,497
Genentech, Inc. · A Phase III Trial of Gdc 9545 in Combination With Palbo in Hr Her2 Neg 1l Mbc · 2021Their institution$25,932
ABBVIE INC. · A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of Abt-165, A Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors · 2021Their institution$25,167
Genentech, Inc. · Tdm1 Extension Study in Mbc Patients · 2020Their institution$19,729
Eli Lilly and Company · Monarch 2- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With Or Without Abemaciclib, A Cdk4 6 Inhibitor, for Women With Hormone Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer · 2020Their institution$16,929
Eli Lilly and Company · Monarch 2- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With Or Without Abemaciclib, A Cdk4 6 Inhibitor, for Women With Hormone Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer · 2021Their institution$15,665
AbbVie Inc. · 2020Their institution$9,728
AbbVie, Inc. · 2019Their institution$5,312
Genentech, Inc. · A Phase III Trial in Adjuvant Her2 Bc Pts · 2021Their institution$5,033
Novartis Pharmaceuticals Corporation · Ribociclib Standard Endocrine Therapy in Patients With Hr Her2 Early Bc at High Amp Intermediate Risk for Recurrence · 2019Their institution$4,165
Eli Lilly and Company · Monarch 2- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With Or Without Abemaciclib, A Cdk4 6 Inhibitor, for Women With Hormone Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer · 2019Their institution$2,381
Genentech, Inc. · A Phase III Trial in Adjuvant Her2 Bc Pts · 2019Their institution$739

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1780640318
Licence
CA C55993, IN 01032928California C55993: Current · expires 2026-11-30
Trained
Tulane University School of Medicine, 1983 · 43 years ago
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
IN 100074080
Taxonomy
Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2006-04-22
NPI last updated
2024-04-23
NPI record certified
2024-04-16

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 269 Campus Dr, Stanford, CA, 94305